Literature DB >> 27695957

Humoral immune responses and viral shedding following vaccination with modified live porcine reproductive and respiratory syndrome virus vaccines.

Adthakorn Madapong1, Gun Temeeyasen1, Kepalee Saeng-Chuto1, Thitima Tripipat1, Wichian Navasakuljinda2, Alongkot Boonsoongnern3, Angkana Tantituvanont4, Dachrit Nilubol5.   

Abstract

The antibody response and pattern of shedding of vaccine virus following vaccination with modified live genotype I or II porcine reproductive and respiratory syndrome virus (PRRSV) vaccines (MLVs) were investigated. Ninety PRRSV-free pigs were divided randomly seven, groups including the NEG, EU1, EU2, US1, US2, US3 and US4 groups. The NEG group was unvaccinated. The EU1, EU2, US1, US2, US3 and US4 groups were vaccinated with the following MLVs: AMERVAC® PRRS, Porcillis® PRRS, Fostera™ PRRS, Ingelvac® PRRS MLV, Ingelvac® PRRS ATP, and PrimePac™ PRRS+ , respectively. Sera were quantitatively assayed for viral RNA using qPCR. Antibody responses were measured using Idexx ELISA and serum neutralization (SN). Shedding of vaccine virus was investigated using sentinel pigs and by detection of viral RNA in tonsil scrapings. Antibody responses were detected by ELISA at 7-14 days post-vaccination (DPV) and persisted at high titers until 84 DPV in all MLV groups. The SN titers were delayed and isolate-specific. SN titers were higher for the homologous virus than for heterologous viruses. Age-matched sentinel pigs introduced into the EU2, US2 and US3 groups at 60 DPV seroconverted. In contrast, sentinel pigs introduced at 84 DPV remained negative in all of the MLV groups. Vaccine viral RNA was detected in tonsil scrapings from the EU2, US2 and US3 groups at 84-90 DPV. No viral RNA was detected beyond 70 DPV in the EU1, US1 and US4 groups. In conclusion, all MLV genotypes induced rapid antibody responses, which were measured using ELISA. The development of SN antibodies was delayed and isolate-specific. However, the shedding pattern was variable and depended on the by virus isolate used to manufacture the vaccine.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27695957     DOI: 10.1007/s00705-016-3084-4

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  11 in total

1.  Dynamics and Differences in Systemic and Local Immune Responses After Vaccination With Inactivated and Live Commercial Vaccines and Subsequent Subclinical Infection With PRRS Virus.

Authors:  Miroslav Toman; Vladimir Celer; Lenka Kavanová; Lenka Levá; Jitka Frolichova; Petra Ondráčková; Hana Kudláčková; Kateřina Nechvátalová; Jiri Salat; Martin Faldyna
Journal:  Front Immunol       Date:  2019-08-06       Impact factor: 7.561

2.  Cell-mediated immune response and protective efficacy of porcine reproductive and respiratory syndrome virus modified-live vaccines against co-challenge with PRRSV-1 and PRRSV-2.

Authors:  Adthakorn Madapong; Kepalee Saeng-Chuto; Alongkot Boonsoongnern; Angkana Tantituvanont; Dachrit Nilubol
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

3.  Comparative evaluation of 4 commercial modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines against heterologous dual Korean PRRSV-1 and PRRSV-2 challenge.

Authors:  Taehwan Oh; Su-Jin Park; Hyejean Cho; Siyeon Yang; Hee Jin Ham; Chanhee Chae
Journal:  Vet Med Sci       Date:  2020-05-21

4.  Heterologous Challenge with PRRSV-1 MLV in Pregnant Vaccinated Gilts: Potential Risk on Health and Immunity of Piglets.

Authors:  Georgios Papakonstantinou; Eleftherios Meletis; Georgios Christodoulopoulos; Eleni D Tzika; Polychronis Kostoulas; Vasileios G Papatsiros
Journal:  Animals (Basel)       Date:  2022-02-12       Impact factor: 2.752

5.  Intranasal delivery of inactivated PRRSV loaded cationic nanoparticles coupled with enterotoxin subunit B induces PRRSV-specific immune responses in pigs.

Authors:  Puwich Chaikhumwang; Adthakorn Madapong; Kepalee Saeng-Chuto; Dachrit Nilubol; Angkana Tantituvanont
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

6.  Safety of PRRSV-2 MLV vaccines administrated via the intramuscular or intradermal route and evaluation of PRRSV transmission upon needle-free and needle delivery.

Authors:  Adthakorn Madapong; Kepalee Saeng-Chuto; Angkana Tantituvanont; Dachrit Nilubol
Journal:  Sci Rep       Date:  2021-11-29       Impact factor: 4.379

7.  Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2.

Authors:  Mario Fragoso-Saavedra; Carmen Ramírez-Estudillo; Diana L Peláez-González; Jorge O Ramos-Flores; Gustavo Torres-Franco; Leandro Núñez-Muñoz; Gabriel Marcelino-Pérez; María G Segura-Covarrubias; Rogelio González-González; Roberto Ruiz-Medrano; Beatriz Xoconostle-Cázares; Amanda Gayosso-Vázquez; Silvia Reyes-Maya; Vianey Ramírez-Andoney; Rogelio A Alonso-Morales; Marco A Vega-López
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

8.  Differences in Humoral Immune Response against the Type 2 Porcine Reproductive and Respiratory Syndrome Virus via Different Immune Pathways.

Authors:  Wen Li; Yangyang Sun; Shijie Zhao; Zhiying Cui; Yu Chen; Pengli Xu; Jing Chen; Yina Zhang; Pingan Xia
Journal:  Viruses       Date:  2022-06-29       Impact factor: 5.818

9.  The effect of a porcine reproductive and respiratory syndrome outbreak on genetic parameters and reaction norms for reproductive performance in pigs1.

Authors:  Austin M Putz; Clint R Schwab; Alysta D Sewell; Derald J Holtkamp; Jeffery J Zimmerman; Kimberlee Baker; Nick V L Serão; Jack C M Dekkers
Journal:  J Anim Sci       Date:  2019-03-01       Impact factor: 3.159

10.  Host Transcriptional Response to Persistent Infection with a Live-Attenuated Porcine Reproductive and Respiratory Syndrome Virus Strain.

Authors:  Jayeshbhai Chaudhari; Chia-Sin Liew; Aspen M Workman; Jean-Jack M Riethoven; David Steffen; Sarah Sillman; Hiep L X Vu
Journal:  Viruses       Date:  2020-07-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.